Table 1 Patient’s clinical characteristics
Variables | 1–2-3 (n = 34) | 1–3-5 (n = 34) | All (n = 68) | P |
|---|---|---|---|---|
Age, years | 29.65 ± 10.50 | 33.82 ± 9.90 | 31.74 ± 10.34 | 0.096 |
Sex, Male, n(%) | 16 (47.06%) | 17 (50.00%) | 33 (48.53%) | 0.808 |
Body mass index, Kg/m2 | 22.15 ± 8.51 | 22.78 ± 7.79 | 22.54 ± 8.12 | 0.896 |
Urine protein, g/24 h | 2.04 ± 1.81 | 1.74 ± 0.93 | 1.89 ± 1.43 | 0.392 |
Serum albumin, g/L | 36.34 ± 4.26 | 37.13 ± 7.24 | 36.62 ± 6.65 | 0.410 |
Serum creatinine, μmol/L | 98.39 ± 38.20 | 105.51 ± 47.16 | 101.95 ± 42.74 | 0.496 |
eGFR, ml/min/1.73m2 | 89.86 ± 39.47 | 79.92 ± 31.23 | 84.89 ± 35.67 | 0.254 |
Lee grade, n(%) | 0.127 | |||
II | 3 (8.82%) | 4 (11.76%) | 7 (10.29%) | |
III | 19 (55.88%) | 18 (54.55%) | 37 (55.22%) | |
IV | 10 (29.41%) | 9 (27.27%) | 19 (28.36%) | |
V | 2 (5.88%) | 3 (9.09%) | 5 (7.46%) | |
MEST-M, n(%) | 34 (100.00%) | 34 (100.00%) | 68 (100.00%) | 1.000 |
MEST-E, n(%) | 9 (26.47%) | 7 (20.59%) | 16 (23.53%) | 0.234 |
MEST-S, n(%) | 11 (32.35%) | 9 (26.47%) | 20 (29.41%) | 0.457 |
MEST-T, n(%) | 0.563 | |||
T1 | 11 (32.35%) | 9 (26.47%) | 20 (29.41%) | |
T2 | 3 (8.82%) | 3 (8.82%) | 3 (8.82%) | |
MEST-C score, n(%) | 1.000 | |||
C1 | 30 (88.24%) | 30 (88.24%) | 60 (88.24%) | |
C2 | 4 (11.76%) | 4 (11.76%) | 8 (11.76%) | |
Crescents(%) | 14.66 ± 8.44 | 11.45 ± 9.37 | 13.05 ± 9.00 | 0.143 |
Follow-up period, months | 6.00 ± 0.00 | 6.00 ± 0.00 | 6.00 ± 0.00 | 1.000 |
Blood pressure, mmHg | ||||
Systolic at the start | 126.75 ± 8.43 | 130.40 ± 9.25 | 129.58 ± 8.88 | 0.345 |
Diastolic at the start | 72.60 ± 7.50 | 73.45 ± 8.21 | 73.10 ± 7.96 | 0.586 |
Systolic at the end | 122.21 ± 7.61 | 124 ± 6.89 | 123 ± 7.21 | 0.611 |
Diastolic at the end | 70.66 ± 6.89 | 72.26 ± 7.43 | 71.39 ± 7.01 | 0.802 |
RAAS inhibition, n(%) | ||||
Prior to enrollment | 18 (52.94%) | 20 (58.82%) | 38 (55.88%) | 0.605 |
During follow-up | 28 (82.35%) | 29 (85.29%) | 57 (83.82%) | 0.780 |